Bictegravir was approved by FDA recently for: (A) Cystic fibrosis, (B) TB, (C) Hypeension, (D) HIV
Answer is D. Bictegravir (an Integrase Inhibitor) is a component of the fixed-dose combination product bictegravir/emtricitabine/tenofovir alafenamide (brand name: Biktarvy), which received marketing approval for the treatment of HIV infection by U.S. Food and Drug Administration in February 2018.